Trial Profile
An Observational Study Of Indian Breast Cancer Patients Receiving Adjuvant Therapy With Aromasin.
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 21 Nov 2013
Price :
$35
*
At a glance
- Drugs Exemestane (Primary)
- Indications Early breast cancer
- Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
- Sponsors Pfizer
- 01 Sep 2012 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 01 Sep 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 18 Apr 2011 Planned End Date changed from 1 Aug 2015 to 1 Aug 2013, according to ClinicalTrials.gov.